Why Whole Foods is Hot
Health Care: Drugs
Biodel Inc. (BIOD: NASDAQ)
$3.70 0.08 | 2.21%
05/23/13 - 11:54 AM ET
138.76K / 59.70K
Vol / Avg. Vol:3.61 / 3.62
Open / Prev. Close:3.61 - 3.74
Today's Range:2.13 - 3.82
52 Wk Range:45.96%
Performance YTD:TheStreet Rating:
Portfolios with BIOD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- Usertesting
- Contributor10 Pharma Stocks Under $3
- Contributor10 Stocks Under $3 With Upside
- Contributor4 Small Stocks With Buyout ...
- UserMy Portfolio
- Contributor$5 Stocks That Analysts Exp...
- Usersinghtelecom Portfolio 1
- UserStocks Elite
Latest BIOD Headlines from TheStreet
- Biodel Reports Second Quarter Fiscal Year 2013 Financial Results 05.08.13 | 07:05 am
- Biodel To Report Second Quarter Fiscal Year 2013 Financial Results On May 8, 2013 05.06.13 | 06:05 am
- Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes 03.28.13 | 06:03 am
- Biodel Reports First Quarter Fiscal Year 2013 Financial Results 02.12.13 | 04:02 pm
- Biodel To Report First Quarter Fiscal Year 2013 Financial Results On February 12, 2013 02.06.13 | 06:02 am
- Biodel To Present At 2013 BIO CEO And Investor Conference 02.05.13 | 06:02 am
- CORRECTION -- Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates 01.24.13 | 09:01 am
- Biodel Reports Positive Top-Line Results From Clinical Study Of Ultra-Rapid-Acting Insulin Analog Candidates 01.24.13 | 06:01 am
- Biodel Reports Fourth Quarter Fiscal Year 2012 Financial Results 12.18.12 | 06:12 am
- Biodel To Report Fourth Quarter Fiscal Year 2012 Financial Results On December 18, 2012 12.14.12 | 07:12 am
Press Releases for BIOD
- Biodel To Host Analyst / Investor Research And Development Meeting On October 11th In New York - PR Newswire 10.05.12 | 04:10 pm
- Biodel To Present At European Association For The Study Of Diabetes On October 2, 2012 In Berlin, Germany - PR Newswire 09.27.12 | 06:09 am
- Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 - PR Newswire 09.13.12 | 06:09 am
- Biodel To Present At 2012 Wedbush PacGrow Lifesciences Management Access Conference - PR Newswire 08.10.12 | 06:08 am
- Biodel Awarded NIH Grant To Develop Concentrated Ultra-Rapid-Acting Insulin Formulations For Use In Artificial Pancreas - PR Newswire 07.26.12 | 06:07 am
- Biodel To Present At JMP Securities Healthcare Conference - PR Newswire 07.10.12 | 06:07 am
- Biodel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement - PR Newswire 06.27.12 | 06:06 am
- Biodel Announces $18.5 Million Private Placement - PR Newswire 06.22.12 | 09:06 am
- Biodel Obtains Exclusive License To Aegis Therapeutics' Technologies For Development And Commercialization Of Glucagon Pharmaceutical Formulations - PR Newswire 06.08.12 | 04:06 pm
- Biodel Announces Data Presentations At American Diabetes Association Annual Meeting - PR Newswire 06.05.12 | 06:06 am
Partner Headlines for BIOD
- Wedbush Securities Reiterates Neutral Rating, $3 PT on Biodel - Benzinga 12.07.12 | 01:12 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 08.14.12 | 09:08 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 07.16.12 | 09:07 am
- Morning Market Losers - Benzinga 06.12.12 | 09:06 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.19.11 | 09:10 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.14.11 | 09:10 am
- Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners - Seeking Alpha 09.29.11 | 08:09 am
- Biotech Catalysts for Third Quarter - Seeking Alpha 06.24.11 | 06:06 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Company News for February 07, 2011 - Corporate Summary - Zacks 02.07.11 | 10:02 am
